 NEWARK, Calif., Aug. 03, 2020 GLOBE NEWSWIRE -- CymaBay Therapeutics, Inc. NASDAQ: CBAY, a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter and six months ended June 30, 2020 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID 13706143. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the companys website at About CymaBay CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis PBC. Seladelpar has received an orphan designation from the US Food and Drug administration FDA and the European Medicine Agency EMA. Seladelpar also received Breakthrough Therapy Designation from the FDA and PRIority MEdicines status from the EMA for PBC.For additional information about CymaBay visit Relations Contact: Glenn Silver Lazar-FINN Partners 973 818-8198 Investor Relations Contact:Hans Vitzthum LifeSci Advisors, LLC 617 430-7578 